An NCI trial shows that giving patients pembrolizumab after surgery for high-risk muscle invasive bladder cancer doubles the median length of time that they remain cancer free, compared with observation alone after surgery.
An NCI trial shows that giving patients pembrolizumab after surgery for high-risk muscle invasive bladder cancer doubles the median length of time that they remain cancer free, compared with observation alone after surgery.